JP2019526571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526571A5 JP2019526571A5 JP2019511720A JP2019511720A JP2019526571A5 JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5 JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019511720 A JP2019511720 A JP 2019511720A JP 2019526571 A5 JP2019526571 A5 JP 2019526571A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- acid
- neurotransmission
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614834.8 | 2016-09-01 | ||
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526571A JP2019526571A (ja) | 2019-09-19 |
| JP2019526571A5 true JP2019526571A5 (OSRAM) | 2020-10-01 |
| JP7066679B2 JP7066679B2 (ja) | 2022-05-13 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511720A Active JP7066679B2 (ja) | 2016-09-01 | 2017-08-25 | 認知症の処置 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (OSRAM) |
| EP (1) | EP3506904B1 (OSRAM) |
| JP (1) | JP7066679B2 (OSRAM) |
| KR (1) | KR102559354B1 (OSRAM) |
| CN (1) | CN109890391B (OSRAM) |
| AU (1) | AU2017318333B2 (OSRAM) |
| CA (1) | CA3034625A1 (OSRAM) |
| DK (1) | DK3506904T3 (OSRAM) |
| ES (1) | ES2847929T3 (OSRAM) |
| GB (1) | GB201614834D0 (OSRAM) |
| HR (1) | HRP20210162T1 (OSRAM) |
| MX (1) | MX384442B (OSRAM) |
| MY (1) | MY187564A (OSRAM) |
| PL (1) | PL3506904T3 (OSRAM) |
| PT (1) | PT3506904T (OSRAM) |
| SG (1) | SG11201901125TA (OSRAM) |
| SI (1) | SI3506904T1 (OSRAM) |
| WO (1) | WO2018041739A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100983301B1 (ko) | 2006-03-29 | 2010-09-20 | 위스타 레보레이토리스 리미티드 | ３,７―다이아미노―１０ｈ―페노티아진염 및 이의 용도 |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| CN109789148A (zh) | 2016-07-25 | 2019-05-21 | 维斯塔实验室有限公司 | 二氨基吩噻嗪的给药和剂量 |
| ES2989458T3 (es) | 2018-07-26 | 2024-11-26 | Wista Lab Ltd | Dosis optimizada de diaminofenotiazinas en poblaciones |
| AU2018440060B2 (en) | 2018-09-05 | 2025-04-10 | Genting Taurx Diagnostic Centre Sdn Bhd | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| EP4146225B1 (en) * | 2020-05-05 | 2024-10-09 | WisTa Laboratories Ltd. | Methylthioninium compounds for use in the treatment of hypoxemia |
| AU2023279800A1 (en) | 2022-05-31 | 2024-12-19 | TauRx Therapeutics Management Ltd | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| WO2024178120A2 (en) * | 2023-02-21 | 2024-08-29 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2003101458A1 (en) * | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| PT2322517T (pt) | 2004-09-23 | 2019-07-30 | Wista Lab Ltd | Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc) |
| KR100983301B1 (ko) * | 2006-03-29 | 2010-09-20 | 위스타 레보레이토리스 리미티드 | ３,７―다이아미노―１０ｈ―페노티아진염 및 이의 용도 |
| MY172157A (en) | 2006-03-29 | 2019-11-15 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| AU2007274057B2 (en) | 2006-07-11 | 2012-12-13 | TauRx Therapeutics Management Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| PL2167095T3 (pl) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| EP2954932B1 (en) * | 2007-10-03 | 2018-09-19 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| BR112012006638B1 (pt) | 2009-09-24 | 2020-05-26 | Wista Laboratories Ltd. | Forma c de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica |
| MX2012003035A (es) | 2009-09-24 | 2012-06-12 | Wista Lab Ltd | Proceso. |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 CA CA3034625A patent/CA3034625A1/en active Pending
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526571A5 (OSRAM) | ||
| JP6795517B2 (ja) | ５−芳香族アルキニル基置換ベンズアミド系化合物並びにその製造方法、薬物組成物及び使用 | |
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| AU2014368961B2 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EP3606525B1 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| HRP20210162T1 (hr) | Liječenje demencije | |
| JP2015532295A5 (OSRAM) | ||
| JP2021503480A (ja) | トラジピタントを用いた胃腸疾患の治療方法 | |
| EP3555100A1 (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| JP6023926B2 (ja) | 認知症治療のための５−ｈｔ４受容体アゴニスト | |
| JP2019521964A5 (OSRAM) | ||
| JP2023534189A (ja) | Ｇａｂａａアルファ５アゴニストおよびｓｖ２ａ阻害剤の組合せ物ならびに認知障害の処置において使用する方法 | |
| BRPI0808353B1 (pt) | Usos de amidas do ácido 3-aril-3-hidróxi-2-amino-propiônico, amidas do ácido 3-heteroaril-3-hidróxi-2-amino-propiônico e compostos relacionados | |
| JP2019518736A5 (OSRAM) | ||
| CN107709326A (zh) | 降低应激诱导的p‑tau的三唑并吡啶和三唑并嘧啶 | |
| EP1715921B1 (en) | Tetrahydroindolone derivatives for treatment of neurological conditions | |
| JP7090344B2 (ja) | セロトニン３受容体アゴニストによる疼痛の治療 | |
| BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| US20090156609A1 (en) | Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds | |
| JPWO2004063201A1 (ja) | 統合失調症治療剤 | |
| JP2010530900A (ja) | 中枢神経系活性を有する置換ピロリジン化合物 | |
| US20100227844A1 (en) | Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease | |
| JPWO2010029958A1 (ja) | 侵害受容性疼痛の新規治療用医薬組成物 | |
| HK40019123A (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |